JGC
OKUR

J. Goldman & Co’s OnKure Therapeutics OKUR Stock Holding History

J. Goldman & Co’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,541
Closed -$968K – 497
2023
Q3 		$1.18M Sell
15,541
-15,066
-49% -$1.02M 0.04% 233
2023
Q2 		$2.01M Buy
+30,607
New +$2.47M 0.07% 208

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

J. Goldman & Co's OKUR Position: Q4 2023 in Review

J. Goldman & Co sold out of OnKure Therapeutics (OKUR) in Q4 2023, closing a stake of 15,541 shares — an estimated $968K sold.

J. Goldman & Co first reported a position in OKUR in Q2 2023 and held it in 2 quarters. The position peaked at $2.01M in Q2 2023. 68 funds tracked by Wall St. Rank hold OKUR as of Q4 2023.

  • J. Goldman & Co reported no remaining OnKure Therapeutics position as of Q4 2023 after selling out during the quarter.
  • J. Goldman & Co sold 15,541 OnKure Therapeutics shares in Q4 2023, an estimated $968K.
  • J. Goldman & Co first reported a position in OnKure Therapeutics in Q2 2023 and held it in 2 quarters.
  • J. Goldman & Co's OnKure Therapeutics position peaked at $2.01M in Q2 2023.
  • 68 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.